Novartis touts latest Zolgensma data as SMA competition against Biogen, Roche heats up

Retrieved on: 2021-06-18 19:52:30

Tags for this article:

Click the tags to see associated articles and topics

Novartis touts latest Zolgensma data as SMA competition against Biogen, Roche heats up. View article details on hiswai:

Excerpt

As Roche's new spinal muscular atrophy (SMA) drug, Evresdi, gains steam, Novartis is hoping some new trial data can help its gene therapy ...

Article found on: www.fiercepharma.com